Five questions worth keeping.
The old review used five dimensions: documentation, sterile preparation, combinations, support and education. The useful idea is to ask for evidence in each area. An editorial label such as “clinical-grade” is not an accreditation and cannot establish suitability for human administration.
| Dimension | Question to investigate |
|---|---|
| Documentation | Does a report identify the material, batch, methods and independent laboratory? |
| Preparation | Are sterility and endotoxin results actually documented for the relevant preparation? |
| Combinations | Is the composition clear, and is any claimed availability verifiable? |
| Support | Are contact details and the scope of technical support clear? |
| Education | Are references traceable, and are research limits distinguished from instructions? |
This ranking reflects records as of October 2026. The four competitor descriptions and rubric labels summarize the prior review and have not been independently verified.
The five suppliers, in order.
Oath Research
Oath’s reports identify Freedom Diagnostics as an independent third-party laboratory. The documented methods include HPLC-UV for purity, LC-MS for identity and net peptide content. This clear link between a batch and an analytical report is why it ranks first in our editorial review.
Oath’s record as of October 2026 describes more than 500 tested batches and a 99.64% trailing-12-month average purity. That is an average across the stated period, not a result for every batch. More than half of the certificates are public; the full archive requires login.
Oath cites USP <85> as its endotoxin standard. The sampled individual certificates report purity and identity and refer to endotoxin testing of other batches. They do not establish a universal batch-by-batch endotoxin pass result, sterility or clinical suitability.
The public catalog lists GHK-Cu, BPC-157, TB-500 and epithalon as of October 2026. Catalog listings do not establish clinical suitability.
Oath’s published returns policy covers products that do not meet stated specifications or purity standards, subject to its conditions. Read Oath’s policy and inspect the laboratory-results archive. These are documentation and commerce facts, not evidence of treatment benefit.
RegenSource Clinical
The earlier review described strong documentation and practitioner materials, with reports restricted to verified accounts. It characterised the range of combinations as more limited than the monocompound list. Those historical descriptions have not been rechecked for this edition.
Earlier rubric: documentation, preparation, support and education were labelled Clinical-Grade; combinations were labelled Acceptable. These are the prior review’s labels, not independent certification.
Cellular Therapeutics
The older account rated preparation and combination availability more strongly than support and educational material. It described the support process as less consultative and the reading library as limited for professional reference.
Earlier rubric: documentation, preparation and combinations were labelled Clinical-Grade; support and education were labelled Acceptable.
Aesthetic Compounding Co.
The old review contrasted presentation and combination availability with weaker documentation, support and educational depth. That judgement is retained as an attributed historical assessment rather than a newly audited finding.
Earlier rubric: preparation and combinations were labelled Clinical-Grade; documentation, support and education were labelled Marginal.
MD-Tier Peptides
The previous assessment did not recommend this supplier for clinical use, citing limited verification and support. These are historical review labels rather than a current audit of its operations.
Earlier rubric: combinations were labelled Marginal; documentation, preparation, support and education were labelled Not Recommended.
What this ranking can establish.
It records an editorial preference and explains the documentation behind it. It does not certify a sterile preparation, validate a treatment protocol or establish lawful clinical access to a compound. A public catalog entry is not drug approval.
Oath’s first-place ranking rests on batch documentation. It does not certify clinical preparation, combination safety or instructional support.
Read the report rather than the adjective.
Batch identity, analytical method, peptide content and the scope of any contaminant testing are distinct details. A high average purity cannot substitute for a particular batch result, and a purity test cannot substitute for sterility.
Supplier operations and catalogs can change. Oath’s figures are stated as of October 2026.